Chad Farley, DPM
Foot Surgery · Lakewood, WANPI 1396820536
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (56.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Arthrex at 34.2% of the total. Reporting peaked in 2022 at $1,456 and has fallen 71.6% since, to $414 in 2025.
Across 27 payments — averaging $157.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$1K
- Summit Surgical Corp.$1K
- Medical Device Business Services, Inc.$656
- Zimmer Biomet$230
- Bioventus LLC$144
- Acera Surgical, Inc.$129
- plus $406 from 9 others
What the payments were for
- Travel & lodging$76418%
- Food & beverage$1,08926%
- Education$2,40056%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 5 | $1,456 |
| Summit Surgical Corp. | 2 | $1,232 |
| Medical Device Business Services, Inc. | 6 | $656 |
| Zimmer Biomet | 2 | $230 |
| Bioventus LLC | 1 | $144 |
| Acera Surgical, Inc. | 1 | $129 |
| Amgen | 1 | $123 |
| Treace Medical Concepts, Inc. | 1 | $84 |
| Nevro Corp. | 2 | $45 |
| Johnson & Johnson | 1 | $36 |
| Averitas Pharma Inc. | 1 | $36 |
| AbbVie | 1 | $26 |
| Trice Medical, Inc. | 1 | $25 |
| Invictus Surgical Incorporated | 1 | $16 |
| Paragon 28, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few foot surgery providers in Washingtonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 58 | $1,692 |
| Terbinafine Hcl | 71 | $1,411 |
| Ciclopirox | 32 | $1,020 |
| Gabapentin | 74 | $623 |
| Naproxen | 45 | $216 |
| Cefdinir | 11 | $192 |
| Meloxicam | 65 | $128 |
| Cephalexin | 19 | $125 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $70 |
Paid to pharmacies, not to this prescriber.
Other foot surgery in Lakewood
- Eddie LoTacoma$13K
- Abdulaziz KimawiFederal Way$4K
- Natalie ChuTacoma$4K
- David GriffinVancouver$2K
- Lyle LorimerSeattle$759
- Ronald DouglasSpokane$745
- Shawn SummersYakima$538
- Samuel LiebsonPort Angeles$319
- Chad SmithPuyallup$261
- Michael SherwinBellingham$151
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.